Top entities: Zealand Pharma, Danske Bank, Nasdaq Copenhagen, Denmark — Danish krone, European Union.

What category does this event fall under?

Business — classified as share buy-back.

What is the sentiment of coverage?

Aggregate sentiment score: 10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Zealand Pharma initiates share buy-back · Zealand Pharma appointed lead manager Danske Bank

Is this event still developing?

This is an active story, last updated Jun 08, 2026. Coverage continues to evolve.

Business share buy-back

Zealand Pharma Share Buy-Back Program

Q: When did this event occur?

First reported May 26, 2026; last updated Jun 08, 2026.

Q: What is the market impact?

Direct. The share buy-back program by Zealand Pharma is generally viewed positively by the market as it can reduce the number of outstanding shares, thereby increasing earnings per share and potentially the stock price.

Analysis based on 10 articles · First reported May 26, 2026 · Last updated Jun 08, 2026

Sentiment

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The share buy-back program by Zealand Pharma is generally viewed positively by the market as it can reduce the number of outstanding shares, thereby increasing earnings per share and potentially the stock price. The program's execution on Nasdaq Copenhagen demonstrates ongoing corporate activity that can influence investor sentiment towards Zealand Pharma.

Biotechnology Financial Services

Event Summary

Zealand Pharma, a biotechnology company, is actively engaged in a share buy-back program, repurchasing its own shares on Nasdaq Copenhagen. The program, which commenced on May 7, 2026, and is set to conclude by October 31, 2026, allows for the repurchase of shares up to a total consideration of DKK 1.3 billion. As of week 23 (June 1 - June 4, 2026), Zealand Pharma has accumulated 751,000 treasury shares, totaling DKK 240,880,840. The company also increased its share capital by 53,183 new shares. Danske Bank has been appointed as the lead manager, making independent trading decisions for the program, which adheres to European Union regulations.

Key Actions

70 Zealand Pharma initiates share buy-back

40 Zealand Pharma appointed lead manager Danske Bank

Entities Involved

stock

Zealand Pharma

Zealand Pharma is executing a share buy-back program to repurchase its own shares, which can positively impact its stock price and shareholder value. The company has repurchased 751,000 shares for DKK 240,880,840 under the program.

Importance 100 Sentiment 10

stock

Danske Bank

Danske Bank has been appointed as the lead manager for Zealand Pharma's share buy-back program, making independent trading decisions on behalf of Zealand Pharma.

Importance 50 Sentiment 0

exch

Nasdaq Copenhagen

Nasdaq Copenhagen is the exchange where the transactions for Zealand Pharma's share buy-back program are being executed.

Importance 30 Sentiment 0

curr

Denmark — Danish krone

The share buy-back program is valued in Danish Krone, with a total consideration of up to DKK 1.3 billion.

Importance 20 Sentiment 0

alliance

European Union

The share buy-back program is carried out in accordance with regulations set by the European Union, specifically the Market Abuse Regulation and the Safe Harbour Regulation.

Importance 10 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard